CREATIVE CHINA (08368) is pleased to announce that the expected annual net profit attributable to shareholders is expected to increase by 42 to 45 million compared to the previous year.
China Creative Holdings (08368) announced that compared to the approximately RMB 24.4 million net profit attributable to owners of the company for the same period in 2024, the company expects to achieve a net profit attributable to owners of the company of RMB 42-45 million for the year ending December 31, 2025. The board of directors believes that the increase in profit for the year is mainly due to an increase in gross profit in the television/film production and film copyright investment departments, revenue from the sale of equity in several subsidiary companies, and a reduction in administrative expenses due to the lack of amortization of intangible assets.
CREATIVE CHINA (08368) announced that compared to the annual net profit of approximately RMB 24.4 million attributable to the owners of the Company for the year ended 2024, the Company expects the annual net profit attributable to the owners of the Company for the year ended December 31, 2025 to be between RMB 42 million and RMB 45 million. The Board of Directors believes that the increase in profit for the year is mainly due to the increase in gross profit of the television drama/film production and film copyright investment departments, the income from the sale of shares of certain subsidiary companies, and the reduction in administrative expenses due to the lack of amortization of intangible assets.
Related Articles

Shenzhen Kangtai Biological Products (300601.SZ): Four-strain influenza virus split vaccines obtained drug registration certificate.

Jiangsu Hengrui Pharmaceuticals (01276): R-Cotonib monotherapy for injection has been approved for new indications.

Lingbao Gold (03330) issued 6.6181 million shares due to the exercise of the convertible bond conversion rights.
Shenzhen Kangtai Biological Products (300601.SZ): Four-strain influenza virus split vaccines obtained drug registration certificate.

Jiangsu Hengrui Pharmaceuticals (01276): R-Cotonib monotherapy for injection has been approved for new indications.

Lingbao Gold (03330) issued 6.6181 million shares due to the exercise of the convertible bond conversion rights.

RECOMMEND

State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026

Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026

Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026


